26 May 2013
Keywords: biogen, bg-12, meets, psoriasis, endpoints, firm, idec
Article | 18 April 2005
US firm Biogen Idec and Fumapharm AG of Lausanne, Switzerland, have announced results from a Phase III study designed to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 April 2005
24 May 2013
© 2013 thepharmaletter.com